Clinical trials: Biting
Denture Retention
A Clinical Bite Force Study of Two Marketed Adhesives Against no Adhesive
The objective of this study will be to compare bite force (BF) measurements over a 12-hour period of a currently marketed denture adhesive cream based on carbomer technology (test), with a positive control and a negative/no…
- Trial name
- NCT03037307
- Testing
- Test Product, Positive Contol, Negative Control
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Lymphoblastic Leukemia
Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
This study is being done to evaluate the rate of hematological response (complete remission/complete remission with partial hematological recovery [CR/CRh*]) induced by blinatumomab in Chinese adults with relapsed/refractory…
- Trial name
- NCT03476239
- Testing
- Blinatumomab, Dexamthasone
- Where
- 23 sites in China
- Volunteers
- 121 people
- Sponsor
- Amgen
Iliac Artery Occlusive Disease
A Clinical Evaluation of the Bard® Luminexx™ Iliac Stent and Delivery System
To determine the safety and effectiveness of the LUMINEXX stent for the proposed indication of treatment of common and/or external iliac artery occlusive disease
- Trial name
- Luminexx (NCT00561457)
- Testing
- Bard Luminexx Iliac Stent and Delivery System
- Volunteers
- 134 people
- Sponsor
- C. R. Bard
Catheter Occlusion, Thrombosis
Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality
To evaluate the efficacy and safety of CUSA-081 (diluted reteplase) in the restoration of central venous access device (CVAD) functionality in participants 18 years and older.
- Trial name
- READY1 (NCT03594175)
- Testing
- CUSA-081, Alteplase
- Where
- 77 sites in United States, Argentina and 5 more
- Volunteers
- 462 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Non-Hodgkin's Lymphoma, Relapsed
Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL
The purpose of this study is to determine whether a continuous infusion of Blinatumomab (MT103) is safe in the treatment of relapsed Non-Hodgkin's Lymphoma.
- Trial name
- NCT00274742
- Testing
- Blinatumomab (MT103)
- Where
- 5 sites in Germany
- Volunteers
- 76 people
- Sponsor
- Amgen Research (Munich) GmbH
Peripheral Arterial Disease
Multi-center Study for Stent Graft System for Peripheral Artery
The utility of GP1101 will be evaluated relative to that of surgical bypass in the treatment of Femoral/Popliteal Arterial Symptomatic Peripheral Arterial Disease.
- Trial name
- VJH11-01 (NCT01575808)
- Testing
- GP1101
- Where
- 15 sites in Japan
- Volunteers
- 133 people
- Sponsor
- W.L.Gore & Associates
Dentine Hypersensitivity, Dental Pain
Dose Response of a Tubule Occlusion Agent
To evaluate the efficacy of two different concentrations of a tubule occlusion agent - calcium sodium phosphosilicate in treatment of dentine hypersensitivity
- Trial name
- NCT01075256
- Testing
- 5% calcium sodium phosphosilicate toothpaste, 7.5% calcium sodium phosphosilicate toothpaste
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- GlaxoSmithKline
Sting
Trial to Test if Antibiotic Ointments & Cream Will Sting After Application on a Minor Wound After Tape Stripping Injury
The purpose of this study is to have subjects report whether or not several antibiotic products sting when they are applied to minor wounds created on the inner arms.
- Trial name
- NCT02320695
- Testing
- Saline, Isopropyl Alcohol, Pain Relieving Cream
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Neoplasms
A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
This study aims to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of GSK3745417 administered alone (Part 1A) or co-administered (Part 2A) with dostarlimab in participants…
- Trial name
- NCT03843359
- Testing
- GSK3745417, Dostarlimab
- Where
- 12 sites in United States, Australia and 6 more
- Volunteers
- 97 people
- Sponsor
- GlaxoSmithKline
Acute Lymphoblastic Leukemia
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to confirm whether the bispecific T cell engager antibody blinatumomab (MT103) is effective and safe in the treatment of patients with relapsed or refractory Acute Lymphoblastic Leukemia (ALL).
- Trial name
- NCT01466179
- Testing
- Blinatumomab
- Where
- 39 sites in United States, France and 4 more
- Volunteers
- 225 people
- Sponsor
- Amgen Research (Munich) GmbH
Atrial Fibrillation, AFib
Stroke Feasibility Study
This is a feasibility study to assess the safety and efficacy of the AtriCure AtriClip when placed via Minimally Invasive Surgical Deployment to the Left Atrial Appendage.
- Trial name
- NCT01997905
- Testing
- AtriClip LAA Exclusion Device
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- AtriCure, Inc.
Acute Lymphoblastic Leukemia
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
The purpose of this study is to determine the dose of the bispecific T cell engager blinatumomab (MT103) in pediatric and adolescent patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and to assess whether this…
- Trial name
- NCT01471782
- Testing
- Blinatumomab
- Where
- 30 sites in United States, Austria and 5 more
- Volunteers
- 93 people
- Sponsor
- Amgen Research (Munich) GmbH
Bruxism, Sleep-Related
A Sensor-enhanced Mouth Guard to Quantitatively Measure Bite Compression Forces.
The goal of this study is to determine if the Otis Brux-Sensor Night Guard (OBSNG) can record the bite compression forces of participants with Bruxism. The main questions it aims to answer is: 1.
- Trial name
- NCT06688474
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Otis Dental, LLC
B-cell Acute Lymphoblastic Leukemia
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to confirm whether the bispecific T cell engager blinatumomab (MT103) is effective, safe and tolerable in the treatment of ALL patients with minimal residual disease.
- Trial name
- BLAST (NCT01207388)
- Testing
- Blinatumomab
- Where
- 75 sites in Austria, Belgium and 9 more
- Volunteers
- 116 people
- Sponsor
- Amgen Research (Munich) GmbH
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
The primary objective was to evaluate the effect of blinatumomab on overall survival when compared to standard of care (SOC) chemotherapy.
- Trial name
- NCT02013167
- Testing
- Blinatumomab, Standard of Care Chemotherapy
- Where
- 117 sites in United States, Australia and 19 more
- Volunteers
- 405 people
- Sponsor
- Amgen
Peripheral Vascular Disease
A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
OSPREY is a multi-center, single arm, non-randomized, prospective clinical trial. Subjects will undergo a superficial femoral artery (SFA) stent procedure using the Misago™ Peripheral Self Expanding stent once all of the…
- Trial name
- OSPREY (NCT01118117)
- Testing
- Misago™ Self-Expanding Stent System
- Where
- 31 sites in United States
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- Terumo Medical Corporation
B-ALL
Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to determine whether the bispecific T-cell engager blinatumomab is effective, safe and tolerable in the treatment of patients with relapsed/refractory B-precursor ALL.
- Trial name
- NCT01209286
- Testing
- Blinatumomab
- Where
- 9 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Amgen Research (Munich) GmbH
Denture Retention
A Clinical Study to Evaluate the Maximum Maxillary Bite Force (BF) When Using Two Novel Denture Adhesives Compared to Using No-Adhesive
The purpose of this study is to investigate the hold properties of two experimental denture adhesives using established maximum incisal BF methodology.
- Trial name
- NCT05173974
- Testing
- Super Poligrip Free, Experimental Denture Adhesive 1, Experimental Denture Adhesive 2
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- HALEON
Extensive Stage Small Cell Lung Cancer
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
The primary aim of this study is to evaluate the efficacy of tarlatamab as assessed by objective response rate (ORR) based on blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1…
- Trial name
- DeLLphi-307 (NCT06502977)
- Testing
- Tarlatamab
- Where
- 12 sites in China
- Volunteers
- 32 people
- Sponsor
- Amgen
Metastatic Castration-resistant Prostate Cancer
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
This is a master protocol designed to evaluate the safety and efficacy of investigational therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT04631601
- Testing
- Acapatamab, Enzalutamide, Abiraterone
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 55 people
- Sponsor
- Amgen